News | May 14, 2012

Boston Scientific Introduces ICD, CRT-D Warranties of Up to 10 Years


May 14, 2012 ? Boston Scientific Corp. announced extended warranties of up to 10 years, depending on the model, for its Energen and Incepta implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). The company said the new warranty program is the longest available in the industry and provides physicians, patients and payers across Europe warranties up to five years longer than other currently-marketed cardiac devices. Following are the devices and their warranties. 

- Energen and Incepta VR ICD, 10-year device warranty     
- Energen and Incepta DR ICD, eight-year device warranty     
- Energen and Incepta CRT-D, six-year device warranty 

"Having such a warranty for devices gives physicians assurance about longer battery life and can provide patients with greater peace of mind. This is a major factor to consider when selecting a specific device to implant," said Dr. Oliver Przibille, FESC, CCB, Herzschrittmacher-Centrum, Frankfurt, Germany. 

"From a psychological point of view, an extended warranty has an extremely positive effect on a patient's perception and acceptance of this therapy, because a long warranty means the manufacturer is confident about the longevity of its devices," said Dr. Roberto Verlato, head of cardiology department, Camposampiero Hospital, Italy. 

Boston Scientific's warranty program is based on real-world data from more than 67,000 devices, which include the company's advanced battery technology that offers greater capacity compared to other ICD and CRT-D batteries and includes numerous energy-saving features. 

Currently, 14 million Europeans have heart failure, and this number may rise to 30 million by 2020 as a result of the aging population and the effectiveness of recent treatments to lengthen patients' survival. Heart failure is associated with frequent hospital admissions, which represent the main driver of treatment costs (67-75 percent). On average, heart failure treatment costs amount to 1-2 percent of each country's total healthcare budget in Europe. 

For more information: www.bostonscientific.com

 


Related Content

News | Implantable Cardioverter Defibrillator (ICD)

February 12, 2024 — BIOTRONIK, a leader in implantable medical device technology, announced today they will solely ...

Home February 12, 2024
Home
News | Implantable Cardioverter Defibrillator (ICD)

October 23, 2023 — Medtronic plc, a global leader in healthcare technology, has received U.S. Food and Drug ...

Home October 23, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 28, 2023 — Is the routine implantation of an implantable cardioverter defibrillator (ICD) in myocardial ...

Home August 28, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 28, 2023 — Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and ...

Home August 28, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

July 18, 2023 — The U.S. Food and Drug Administration (FDA) has issued a Class I recall on the Medtronic ICDs and CRT-Ds ...

Home July 18, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

March 7, 2023 — Ninety-five percent of athletes with a diagnosed and treated genetic heart disease experienced no ...

Home March 07, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

February 17, 2023 — Medtronic plc has received CE (Conformité Européenne) Mark for the Aurora EV-ICD MRI SureScan ...

Home February 17, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 29, 2022 — Medtronic plc announced that its investigational EV ICD System – a first-of-its-kind defibrillator ...

Home August 29, 2022
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 18, 2022 — A first-in-human multicenter trial involving Mayo Clinic used a new ablation technique for patients ...

Home August 18, 2022
Home
Subscribe Now